Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study
Latest Information Update: 11 Dec 2024
At a glance
- Drugs Tislelizumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms FIL_Tisle-HL
- 09 Dec 2024 Planned End Date changed from 1 Apr 2029 to 1 Nov 2029.
- 09 Dec 2024 Planned primary completion date changed from 1 Apr 2027 to 1 Nov 2027.
- 19 Jul 2024 Status changed from not yet recruiting to recruiting.